<DOC>
	<DOCNO>NCT01525173</DOCNO>
	<brief_summary>This study evaluate efficacy safety either bimatoprost 0.01 % ophthalmic solution ( Lumigan® ) alone bimatoprost 0.01 % ophthalmic solution ( Lumigan® ) brimonidine tartrate 0.1 % ophthalmic solution ( Alphagan® P ) combination patient previously treat latanoprost 0.005 % ophthalmic solution monotherapy require additional intraocular pressure ( IOP ) lower medication .</brief_summary>
	<brief_title>A Safety Efficacy Study ALPHAGAN® P LUMIGAN® Subjects Previously Treated With Latanoprost Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Ocular hypertension glaucoma least 1 eye Visual acuity 20/100 good eye Corneal refractive laser surgery ( LASIK , LASEK , PRK , RK ) study eye ( ) Intraocular glaucoma surgery past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>